• Explore /
  • Poster
  • / DEDUCTIVE: A study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma—Phase Ib results.

DEDUCTIVE: A study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma—Phase Ib results.

Abstract Poster

Authors

null

Renuka V. Iyer

Roswell Park Comprehensive Cancer Center, Buffalo, NY

Renuka V. Iyer , Daneng Li , Farshid Dayyani , Alexandria T. Phan , Michael N. Needle , Thomas Adam Abrams

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03970616

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 294)

DOI

10.1200/JCO.2021.39.3_suppl.294

Abstract #

294

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2018 Gastrointestinal Cancers Symposium

Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.

Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.

First Author: Sunyoung S. Lee

First Author: Renuka V. Iyer

First Author: Michael Thomas Mark

First Author: Kazuomi Ueshima